首页> 美国卫生研究院文献>Journal of Medicine and Life >Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation
【2h】

Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation

机译:脑溶素在中风康复过程中减少痉挛的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim: This study assessed the efficacy of Cerebrolysin on post-stroke spasticity, motor recovery, and global functions in an outpatient rehabilitation setting.Methods: In this retrospective comparison study, Cerebrolysin was administered at a daily dosage of 10 ml for over 30 days as an intramuscular injection. Control patients did not receive Cerebrolysin. All the patients participated in a standardized physical and occupational rehabilitation therapy for one month at least two times per week. Efficacy was assessed at day 30 by using the Modified Ashworth Scale (MAS) for spasticity and the Manual Muscle Testing (MMT) for motor recovery. Global function was assessed by the modified Rankin Scale (mRS) at day 30.Results: A total of 50 patients were eligible for participation according to the inclusion and exclusion criteria. Of these, 23 patients were treated with Cerebrolysin and 27 patients represented the control group. No significant group differences were observed at baseline. Patients treated with Cerebrolysin experienced a significant reduction of spasticity in muscles of the upper and lower limbs, whereas only minor changes were observed in the control group. In the Cerebrolysin group, differences were statistically significant at day 30. Significant improvements of muscle strength and global functions were observed in both groups at day 30. Cerebrolysin was safe and well tolerated.Conclusion: Cerebrolysin had a beneficial effect on post-stroke spasticity in an outpatient rehabilitation setting; intramuscular treatment for over 30 days was safe and well tolerated.
机译:目的:这项研究评估了脑啡肽酶在门诊康复环境中对中风后痉挛,运动恢复和整体功能的功效。方法:在这项回顾性比较研究中,脑啡肽酶以10毫升的日剂量服用,持续30天以上。肌肉注射。对照患者未接受脑溶素。所有患者每周至少两次参加标准化的物理​​和职业康复治疗,为期1个月。在第30天通过使用改良的Ashworth量表(MAS)评估痉挛和使用人工肌肉测试(MMT)评估运动恢复来评估疗效。在第30天,通过改良的Rankin量表(mRS)评估整体功能。结果:根据纳入和排除标准,共有50名患者符合入组条件。在这些患者中,有23例接受脑溶血素治疗,而27例为对照组。在基线时未观察到显着的组差异。脑溶素治疗的患者上肢和下肢的肌肉痉挛明显减少,而对照组仅观察到较小的变化。在脑溶素组中,第30天差异具有统计学意义。在第30天,两组均观察到肌肉力量和整体功能的显着改善。脑溶素安全且耐受性良好。结论:脑溶素对脑卒中后痉挛具有有益作用门诊康复环境;肌内治疗30天以上是安全的,耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号